[at noodls] – Proceeds to Advance SEAMLESS, the Ongoing Phase 3 Trial of Sapacitabine in Elderly Patients With Newly Diagnosed AML BERKELEY HEIGHTS, N.J., Dec. 17, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click here to view […]
[at noodls] – Median Overall Survival is 238 days, or Approximately 8 Months, and 1-Year Survival is 35% With an Overall Response Rate of 41% in Elderly Patients With Newly Diagnosed AML BERKELEY HEIGHTS, N.J., Dec. … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboardSee who Cyclacel is hiring next, click […]
[at noodls] – – Enrollment in SEAMLESS Phase 3 study of sapacitabine proceeding as planned; updated survival data from the pilot/lead-in stage of SEAMLESS to be presented at the upcoming annual meeting of the American … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – BERKELEY HEIGHTS, N.J., Nov. 7, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – BERKELEY HEIGHTS, N.J., Nov. 6, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today multiple posters presented on the Company’s … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, Nov. 5, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP); (Cyclacel or the Company), a biopharmaceutical … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML Updated Survival Data From a Pilot Study and Lead-In Phase of SEAMLESS … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – BERKELEY HEIGHTS, N.J., Oct. 15, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), will host a conference call today to discuss updated data … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – BERKELEY HEIGHTS, N.J., Oct. 2, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that … moreView todays social media effects on CYCCPView the latest stocks trending across Twitter. Click to view dashboard […]
